Macrophage-targeted aerosol inhalation PS-SR nanoparticles as well as preparation method and application thereof
SHP099 and R848 were delivered to macrophages by atomizing inhalation of PS-SR nanoparticles, activate M1 macrophages, block tumor cell escape, and activate T cell immunity, solving the problems of inconvenience in intravenous injection and systemic inflammatory response. It has achieved efficient inhibition and treatment convenience for metastatic tumors.
Patent Information
- Application Number
- CN202410959462.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
AI Technical Summary
Existing intravenous anti-tumor treatments are inconvenient to patients, resulting in low patient compliance, and free R848 administration will cause a nonspecific systemic inflammatory response, requiring a more precise regulation of R848 activity to improve treatment Effect.
Develop atomized inhalation PS-SR nanoparticles targeting macrophages, and deliver drugs to macrophages by combining SHP099 and R848 in phosphatidylserine liposomes. The cells, activate M1 macrophages, block tumor cell escape, and activate T cell immunity to suppress tumors.
The polarization of M2 macrophages into M1 type is achieved, which enhances the tumor cell clearance ability of macrophages, activates T cell immunity, and achieves efficient inhibition of metastatic tumors, reduces systemic inflammatory response, and improves the convenience of treatment. Sex and effect.
Smart Images

Figure CN118903047A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to PS-SR nanoparticles targeted for macrophages by atomization inhalation, and a preparation method and application thereof. Background Art
[0002] Tumor-associated macrophages account for more than 50% of the tumor as a whole and are an important type of immune cell in the tumor. Tumor-associated macrophages have two phenotypes with different functional states, M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotypes. M1 macrophages can phagocytize tumor cells to inhibit tumor growth and recurrence, while M2 macrophages are just the opposite, and their main function is to promote tumor cell growth and invasion. Resiquimod (R848) is an agonist of Toll-like receptors 7 and 8 (TLR7 / TLR8), an immune response regulator with TLR7 / 8 agonist activity, inducing upregulation of cytokines such as TNF-α, IL-12 and NO. It has been reported that R848 can polarize pro-tumor macrophages into anti-tumor macrophages for immunotherapy. However, the administration of free R848 can cause nonspecific systemic inflammatory responses, which is greatly limited in clinical application. Therefore, new strategies are needed to more accurately regulate the activity of R848.
[0003] After CD47 binds to SIRPα, it transmits a "don't eat me" signal to macrophages, thereby inhibiting the phagocytosis of tumor cells by macrophages, allowing tumor cells to escape immune surveillance. SHP099 is an orally active SHP2 inhibitor that can effectively block the downstream protein SHP2 of CD47-SIRPα in tumor cells and macrophages, blocking the escape of tumor cells in macrophages, and enhancing the ability of macrophages to clear tumor cells.
[0004] Phosphatidylserine (PS), also known as serine phospholipids and diacylglycerol phosphoserine, is a ubiquitous phospholipid that is usually located in the inner layer of the cell membrane. It is one of the cell membrane components and is related to a series of membrane functions. When cells undergo apoptosis, PS is expressed externally on the cell membrane. Macrophages recognize PS expressed by apoptotic cells and then remove them through efferocytosis.
[0005] Therefore, it is essential to develop a nanoformulation that can effectively target macrophages, deliver R848 and SHP099 into macrophages, and reduce adverse reactions of the body while taking advantage of the characteristics of macrophages that recognize and eliminate cells expressing PS. Currently, intravenous administration is a common means of anti-tumor treatment, but intravenous injection often brings a lot of inconvenience and pain to patients, and usually requires professionals to perform intravenous injection operations, which causes patients to go to the hospital frequently for treatment, thus affecting patient compliance. Therefore, it is of great significance to explore a more convenient, effective and patient-acceptable treatment method. It brings hope for improving the treatment effect and prognosis of cancer patients. Summary of the invention
[0006] In view of the above-mentioned deficiencies, the present invention provides a PS-SR nanoparticle for aerosol inhalation targeting macrophages, and a preparation method and application thereof. The PS-SR nanoparticles provided by the present invention include SHP099, R848 and PS liposomes. The PS-SR nanoparticles provided by the present invention can target macrophages by aerosol inhalation, and deliver R848 and SHP099 into macrophages. R848 polarizes M2 macrophages to M1 type, releases proinflammatory cytokines to achieve anti-tumor effects; SHP099 blocks tumor cells from escaping in macrophages by inhibiting SHP2, a downstream protein of CD47-SIRPα in macrophages, thereby enhancing the tumor cell clearance ability of macrophages. Activated macrophages present antigens to T cells, effectively activating the body's T cell immunity, further killing cancer cells at the tumor site, and achieving efficient inhibition of metastatic tumors.
[0007] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0008] In one aspect, the present invention provides a PS-SR nanoparticle for aerosol inhalation, wherein the PS-SR nanoparticle comprises SHP099, R848 and PS liposomes, and the PS liposomes comprise brain PS, DSPC and cholesterol;
[0009] The structural formula of SHP099 is shown in Formula I, and the structural formula of R848 is shown in Formula II;
[0010]
[0011] Specifically, the concentration ratio of SHP099, R848 and PS liposome is 2-4:4-6:3-3.5.
[0012] Preferably, the concentration ratio of SHP099, R848 and PS liposome is 3:5:3.25.
[0013] Specifically, the concentration ratio of brain PS, DSPC and cholesterol in the PS liposome is 4-6:3-5:0.5-2.
[0014] Preferably, the concentration ratio of brain PS, DSPC and cholesterol in the PS liposome is 5:4:1.
[0015] Specifically, the particle size of the PS liposome is ≤100 nm.
[0016] Specifically, the preparation method of the PS liposome is:
[0017] S1. Brain PS, DSPC and cholesterol were added to chloroform solution, stirred for 5 min, and evaporated under reduced pressure to form a PS lipid film;
[0018] S2. The PS lipid membrane is hydrated and purified to form PS liposomes.
[0019] Preferably, the PS-SR nanoparticles are atomized by a nebulizer.
[0020] Specifically, the preparation method of the PS-SR nanoparticles comprises:
[0021] S1. Evenly mix an organic solvent containing SHP099 and an organic solvent containing R848 to obtain a mixed solution;
[0022] S2, adding PS liposomes to the mixed solution, evaporating under reduced pressure to form a PS-SR lipid membrane;
[0023] S3. The PS-SR lipid film is hydrated and purified to form PS-SR nanoparticles.
[0024] Specifically, the input volumes of the organic solvent containing SHP099 and the organic solvent containing R848 in step S1 are 1:1-2.
[0025] Preferably, in step S1, the input volume of the organic solvent containing SHP099 and the organic solvent containing R848 is 1:1.5.
[0026] Specifically, the organic solvent containing SHP099 in step S1 contains 5-15 mg / mL SHP099.
[0027] Preferably, the organic solvent containing SHP099 in step S1 contains 10 mg / mL SHP099.
[0028] Specifically, the organic solvent containing R848 in step S2 contains 5-15 mg / mL R848.
[0029] Preferably, the organic solvent containing R848 in step S2 contains 10 mg / mL R848.
[0030] Preferably, the organic solvent in step S1 includes methanol.
[0031] Specifically, step S1 includes mixing the SHP099 methanol solution and the R848 methanol solution evenly, adding the mixture into a round-bottom flask containing chloroform, and stirring.
[0032] Preferably, the volume ratio of the mixed solution of the SHP099 methanol solution and the R848 methanol solution to chloroform is 1:8.
[0033] Specifically, the input volume ratio of the PS liposomes described in step S2 to the mixed solution is 7:20.
[0034] Specifically, the purpose of evaporating under reduced pressure in step S2 is to evaporate the organic solvent.
[0035] Specifically, the solution used for hydration in step S3 includes but is not limited to PBS, physiological saline or purified water.
[0036] Preferably, the solution used for hydration in step S3 is PBS.
[0037] Specifically, the hydration in step S3 includes the following steps: (1) adding PBS and ultrasonically hydrating in a water bath for 5 minutes; (2) ultrasonically hydrating at 70° C. for another 2 minutes using a 20W probe.
[0038] Specifically, the purification described in step S3 includes filtration and dialysis.
[0039] Preferably, the filter membrane used for the filtration is a 0.45 μm filter membrane.
[0040] Preferably, the purpose of the filtration is to remove free lipid aggregates.
[0041] Preferably, the dialysis process is as follows: encapsulating the PS-SR in a dialysis bag with a molecular cutoff of 500, and placing the bag in a dialysis tank containing ddH2O for 4 hours.
[0042] Preferably, the purpose of the dialysis is to remove unentrapped free drugs.
[0043] In certain embodiments, the PS-SR concentration can be adjusted by adjusting the input amount of SHP099, R848, PS liposomes or the added amount of PBS.
[0044] In another aspect, the present invention provides a method for preparing the above-mentioned PS-SR nanoparticles, the preparation method comprising:
[0045] S1. Evenly mix an organic solvent containing SHP099 and an organic solvent containing R848 to obtain a mixed solution;
[0046] S2, adding PS liposomes to the mixed solution, evaporating under reduced pressure to form a PS-SR lipid membrane;
[0047] S3. The PS-SR lipid film is hydrated and purified to form PS-SR nanoparticles.
[0048] Specifically, the input volumes of the organic solvent containing SHP099 and the organic solvent containing R848 in step S1 are 1:1-2.
[0049] Preferably, in step S1, the input volume of the organic solvent containing SHP099 and the organic solvent containing R848 is 1:1.5.
[0050] Specifically, the organic solvent containing SHP099 in step S1 contains 5-15 mg / mL SHP099.
[0051] Preferably, the organic solvent containing SHP099 in step S1 contains 10 mg / mL SHP099.
[0052] Specifically, the organic solvent containing R848 in step S2 contains 5-15 mg / mL R848.
[0053] Preferably, the organic solvent containing R848 in step S2 contains 10 mg / mL R848.
[0054] Preferably, the organic solvent in step S1 includes methanol.
[0055] Specifically, step S1 includes mixing the SHP099 methanol solution and the R848 methanol solution evenly, adding the mixture into a round-bottom flask containing chloroform, and stirring.
[0056] Preferably, the volume ratio of the mixed solution of the SHP099 methanol solution and the R848 methanol solution to chloroform is 1:8.
[0057] Specifically, the input volume ratio of the PS liposomes described in step S2 to the mixed solution is 7:20.
[0058] Specifically, the purpose of evaporating under reduced pressure in step S2 is to evaporate the organic solvent.
[0059] Specifically, the solution used for hydration in step S3 includes but is not limited to PBS, physiological saline or purified water.
[0060] Preferably, the solution used for hydration in step S3 is PBS.
[0061] Specifically, the hydration in step S3 includes the following steps: (1) adding PBS and ultrasonically hydrating in a water bath for 5 minutes; (2) ultrasonically hydrating at 70° C. for another 2 minutes using a 20W probe.
[0062] Specifically, the purification described in step S3 includes filtration and dialysis.
[0063] Preferably, the filter membrane used for the filtration is a 0.45 μm filter membrane.
[0064] Preferably, the purpose of the filtration is to remove free lipid aggregates.
[0065] Preferably, the dialysis process is as follows: encapsulating the PS-SR in a dialysis bag with a molecular cutoff of 500, and placing the bag in a dialysis tank containing ddH2O for 4 hours.
[0066] Preferably, the purpose of the dialysis is to remove unentrapped free drugs.
[0067] In certain embodiments, the PS-SR concentration can be adjusted by adjusting the input amount of SHP099, R848, PS liposomes or the added amount of PBS.
[0068] In another aspect, the present invention provides use of the PS-SR nanoparticles in the preparation of anti-tumor drugs.
[0069] Specifically, the dosage form of the drug includes solution, suspension or aerosol.
[0070] Specifically, the PS-SR nanoparticles target macrophages and deliver R848 and SHP099 into macrophages to achieve anti-tumor effects.
[0071] Specifically, the tumor includes metastatic tumor.
[0072] Preferably, the tumor comprises lung cancer metastasis, breast cancer metastasis, colorectal cancer metastasis, gastric cancer metastasis, liver cancer metastasis, pancreatic cancer metastasis or prostate cancer metastasis.
[0073] Further preferably, the tumor is a lung metastasis of breast cancer.
[0074] In yet another aspect, the present invention provides a pharmaceutical composition comprising the PS-SR nanoparticles.
[0075] The beneficial effects of the present invention are:
[0076] The PS-SR nanoparticles provided by the present invention can target macrophages through atomization inhalation, and deliver R848 and SHP099 into macrophages. R848 polarizes M2 macrophages to M1 type, releases pro-inflammatory cytokines to achieve anti-tumor effects; SHP099 inhibits the downstream protein SHP2 of CD47-SIRPα in macrophages, blocks the escape of tumor cells in macrophages, and enhances the tumor cell clearance ability of macrophages. Activated macrophages present antigens to T cells, effectively activating the body's T cell immunity, further killing cancer cells in the tumor site, and achieving efficient inhibition of metastatic tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] Figure 1 Characterization of nano drug PS-SR; A in the figure is the particle size PDI diagram of PS; B is the particle size PDI diagram of PS-SR; C is TEM; D is the storage stability of PS-SR.
[0078] Figure 2 This is the high performance liquid chromatogram of R848.
[0079] Figure 3 This is the high performance liquid chromatogram of SHP099.
[0080] Figure 4 This is the HPLC chromatogram of PS-SR.
[0081] Figure 5 It is a cell uptake experiment diagram; A in the figure shows the uptake of cy5.5-labeled PS-SR by different cells; B shows the uptake of PS-SR by three cells at different concentrations after incubation for 4 hours; C shows the uptake of PS-SR by three cells at different time periods at a concentration of 3 mg / L.
[0082] Figure 6 Figure 2 is a polarization experiment diagram of macrophages; A and E in the figure are the expression of Arg-1, a marker protein of M2 type; B and F are the expression of CD206, a marker protein of M2 type; C and G are the expression of CD80, a marker protein of M1 type; D and H are the expression of iNOS, a marker protein of M1 type.
[0083] Figure 7 Figure 1 shows the cell phagocytosis experiment and cytotoxicity experiment. A in the figure shows the phagocytosis of macrophages on tumor cells detected by flow cytometry. B shows the F4 / 80 + GFP + Double positive ratio; C is CLSM detection of macrophage phagocytosis of tumor cells; D is Elisa detection of NO expression in cell supernatant; E is Elisa detection of TNF-α expression in cell supernatant; F is live and dead cell staining; G is macrophage viability.
[0084] Figure 8 This is a picture of the mouse fluorescence imaging experiment.
[0085] Fig. 9 Figure 2 is a tumor inhibition experiment diagram; A in the figure is H&E staining; B is Ki67 and TUNEL staining.
[0086] Fig.10 For immune cell analysis; AH in the figure are immune cell analysis by flow cytometry; I is a CD4 fluorescent staining section of lung tumor tissue; J is a CD8 fluorescent staining section of lung tumor tissue; left in the figure represents the left lung of the mouse, and right represents the right lung of the mouse.
[0087] Fig.11 Lung tissues of mice were obtained and stained with H&E after treatment.
[0088] Fig.12 This is an in vivo biosafety analysis; A in the figure is H&E staining of the heart, liver, spleen, lungs and kidneys; B is the change in mouse body weight; C is a biochemical analysis of blood samples. DETAILED DESCRIPTION
[0089] The present invention will be further described in detail below by way of examples. The following examples are only a part of the present invention and are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are not specifically stated, and the materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.
[0090] Example 1 Preparation of PS-SR
[0091] 1. Preparation
[0092] (1) Preparation of PS-SR
[0093] 100 μL of SHP099 methanol solution (10 mg / mL) and 150 μL of R848 methanol solution (10 mg / mL) were mixed and added to a round-bottom flask containing 2 mL of chloroform, stirred at 600 rpm for 2 minutes, 70 μL of liposomes (20 mM, brain PS: DSPC: cholesterol = 5: 4: 1, CHCl3 solution) were added to the flask, stirred for 5 minutes, and then chloroform and methanol were evaporated under reduced pressure to form a lipid film. Drug-loaded liposomes PS-SR were formed by adding 1 ml of PBS (0.1 M, pH = 7.4) and hydrating under water bath sonication for 5 minutes, and then rehydrating at 70°C, 20W probe sonication for 2 minutes. The resulting NPs were filtered with a 0.45 μm membrane to remove free lipid aggregates, dialyzed for 4 hours to remove unentrapped free drugs, and stored at 4°C. The purified drug-loaded liposome PS-SR contained 0.4 mg / mL SHP099, 0.667 mg / mL R848, and 0.433 mg / mL PS liposomes, and the concentration of the prepared PS-SR was 1.5 mg / mL.
[0094] (2) PS preparation
[0095] 70 μL of PS liposomes (20 mM, brain PS: DSPC: cholesterol = 5: 4: 1, CHCl3 solution) were added to the flask, stirred for 5 minutes, and then chloroform was evaporated under reduced pressure to form a lipid film. Empty liposome PS was obtained by adding 1 ml of PBS (0.1 M, pH = 7.4) and hydrating for 5 minutes under water bath sonication, and then rehydrating for 2 minutes at 70°C and 20W probe sonication. The resulting NPs were filtered with a 0.45 μm membrane to remove free lipid aggregates, and dialyzed for 4 hours to remove, and stored at 4°C.
[0096] (3) PS-SR atomization
[0097] Aerosol (nebulized PS-SR) was generated by a nebulizer connected to the animal box through a tube. Unanesthetized mice were placed in a sealed box and exposed to the aerosol at an air flow rate of level 1 for 10 minutes each time, during which 1 mL of the solution in the nebulizer was nebulized.
[0098] 2. Characterization and storage stability
[0099] The particle sizes of PS and PS-SR were measured by DLS. Figure 1 A and Figure 1As shown in Figure B, the particle size and PDI of PS are 83.04 nm and 0.264, respectively, and the particle size and PDI of PS-SR are 114.6 nm and 0.176, respectively. TEM images show that PS and PS-SR can be assembled into spherical nanoparticles with good dispersion, and the atomized PS-SR still maintains the morphology of spherical nanoparticles ( Figure 1 In addition, to evaluate the stability of PS-SR, the particle size and distribution of PS-SR were monitored by DLS over six days. As expected, PS-SR maintained good stability over six days ( Figure 1 D).
[0100] 3. Encapsulation rate
[0101] HPLC confirmed that the absorption peaks of R848 and SHP099 appeared in PS-SR ( Figure 4 ), indicating that PS-SR successfully encapsulated R848 and SHP099. The encapsulation efficiency of R848 and SHP099 in the PS-SR prepared in this experiment was 44.4±8%, and 40±8%.
[0102] Example 2 In vitro cell experiment
[0103] 1. Cellular uptake experiment
[0104] In order to evaluate the targeting of PS to macrophages, different concentrations of PS-SR were incubated with mouse breast cancer cells 4T1, mouse embryonic fibroblasts 3T3, and mouse alveolar macrophages MH-S. The specific process was as follows: 4T1, 3T3, and MH-S cells were co-cultured with cy5.5-labeled PS-SR (1, 3, 5 mg / L) for 2, 4, and 8 hours, and then the cells were washed three times with PBS and stained with the nuclear dye Hoechst 33342 for 15 minutes.
[0105] Fluorescence confocal microscopy (CLSM) was used to observe the uptake of cy5.5-labeled PS-SR in different cells, such as mouse breast cancer cells 4T1, mouse embryonic fibroblasts 3T3, and mouse alveolar macrophages MH-S. Figure 5 A).
[0106] PS-SR was incubated with the three cell lines at different concentrations and for different times. It can be observed that the uptake of PS-SR by the three cell lines showed time gradient dependence and concentration gradient dependence. In addition, among the three cell lines, MH-S had the highest uptake of PS-SR regardless of time gradient or concentration gradient ( Figure 5 B), the flow cytometry results also reached the same conclusion ( Figure 5C) in the figure shows that PS successfully mediated the targeting performance of nanoparticles to macrophages, providing a powerful platform for PS to successfully deliver R848 and SHP099 to macrophages.
[0107] 2. Polarization of macrophages
[0108] R848 can polarize tumor-promoting M2 macrophages into anti-tumor M1 macrophages, and M1 and M2 macrophages have different surface marker proteins. In order to observe the changes in marker proteins on the surface of macrophages after treatment with different drugs, immunofluorescence staining was performed on the treated MH-S cells, and the expression of different proteins was observed under CLSM. The specific process is:
[0109] LPS or IL-4 (50 ng / mL) was incubated with MH-S cells for 48 h and then replaced with SHP099 (3 mg / L), R848 (5 mg / L), SHP1099 (3 g / L) + R848 (5 mg / L), or PS-SR (11.158 mg / L) for 48 h. The cells were washed three times with PBS and then fixed with 4% paraformaldehyde for 15 min and exposed to 0.1% Triton for 5 min. 10% goat serum was then added to seal the cells for 1 h. Next, the cells were cultured with monoclonal antibodies anti-iNOS (1:500), anti-CD80 (1:200), and anti-Arg-1 (1:200). The next day, the cells were stained with goat anti-rabbit IgG (H+L) labeled with Alexa Fluor 488 (1:500) for 1 h and re-stained with DAPI for 15 min. Afterwards, green fluorescence was detected and counted using CLSM.
[0110] like Figure 6 As shown in the figure, in the group treated with R848, the expression of M2 marker proteins Arg-1 and CD206 on macrophages was reduced to a certain extent ( Figure 6 A and Figure 6 B), and in all drug treatment groups (except IL-4 and LPS treatment groups), PS-SR downregulated these two proteins the most. At the same time, CD80 and iNOS, marker proteins of M1 type on macrophages, were also upregulated in the group containing R848. Not surprisingly, the upregulation effect was most obvious in the PS-SR group, showing strong green fluorescence. However, SHP099 had little effect on the polarization of macrophages. The fluorescence statistics reached a consistent conclusion, which showed that R848 could successfully polarize M2 macrophages into M1 macrophages, laying a successful foundation for the anti-tumor effect of PS-SR in polarizing macrophages in vivo.
[0111] 3. Cell phagocytosis and cytotoxicity experiments
[0112] SHP2 protein is a signal protein downstream of macrophages mediated by the engagement of CD47 protein on tumor cells and SIRPα on macrophages. It is responsible for the activity of actin involved in phagocytosis downstream of CD47-SIRPα signal. Inhibition of SHP2 protein can block the escape pathway of CD47-SIRPα mediated by tumor cells and macrophages. After treating macrophages MH-S with different drugs, the phagocytic ability of macrophages for tumor cells was detected by flow cytometry and CLSM. The specific process is as follows:
[0113] PS-SR (11.158 mg / L) was cultured with MH-S cells for 48 hours. Next, 4T1-GFP cells were added for 2 hours (macrophages: 4T1-GEP cells = 3:1). After washing with PBS, the cells were fixed with 4% paraformaldehyde for 15 minutes, then permeabilized with 0.1% Triton and replaced with 10% goat serum for 1 hour. Monoclonal antibody anti-CD80 (1:500) was added and incubated overnight at 4°C, and goat anti-rabbit IgG (h+L) labeled with Alexa Fluor 647 (1:500). After incubation with SHP099 (100 mg / L), R848 (166.7 mg / L), SHP099 and R848 (166.7 mg / L), or PS-SR (371.9 mg / L) for 6 h, MH-S cells were stained with fluorescent monoclonal antibody F4 / 80 (bound to PB450) and studied by flow cytometry.
[0114] Depend on Figure 7 As shown in A, in all groups containing SHP099, the phagocytic ability of macrophages to tumor cells increased. R848 also slightly increased the phagocytic ratio of macrophages to tumor cells due to its polarization effect. The PS-SR treatment group had the highest double positive ratio ( Figure 7 B), indicating that under the effective delivery of PS-SR, SHP099 more effectively increased the inhibition of SHP2 protein, thereby increasing the phagocytic ability of macrophages. The 3D image displayed by the confocal results more intuitively shows the effect of macrophages engulfing tumor cells ( Figure 7 C).
[0115] In addition, in order to detect the levels of pro-inflammatory cytokines secreted by macrophages after drug treatment, we used Elisa kits to detect the amounts of NO and TNF-α in the cell supernatant after drug treatment. Figure 7 D and Figure 7As can be seen from Figure E, the amount of NO and TNF-α secreted by macrophages in the positive control group increased sharply after LPS treatment, and the levels of these two cytokines in the group containing R848 also increased to a certain extent. Compared with the IL-4 treatment group, the cytokine secretion in the group containing R848 was more than twice that of the IL-4 treatment group, which provided a basis for the subsequent verification of macrophages killing tumor cells through pro-inflammatory cytokines by live and dead cell staining ( Figure 7 F) provides data support. We did not observe any direct killing effect of SHP099, R848 or PS on macrophages ( Figure 7 This further indicates that PS-SR achieves its anti-tumor effect by modifying macrophages rather than targeting tumor cells.
[0116] Example 3 Animal Experiment
[0117] 1. Mouse fluorescence imaging
[0118] Six-week-old female Balb / c mice were injected with 10 6 4T1 cells were used to establish a mouse breast cancer lung metastasis model. After 14 days, the mice were subjected to aerosol inhalation of PS-SR (labeled with cy5.5) using a nebulizer, with an inhalation volume of 1 mL. Fluorescence imaging of the main organs of the mice was performed 1 hour, 24 hours, and 48 hours after the end of the inhalation to observe the accumulation of PS-SR in the lungs.
[0119] Depend on Figure 8 As can be seen from A, the retention time of cy5.5-labeled PS-SR in the lungs of mice is as long as 48 hours. The lungs show the strongest red fluorescence at 1 hour, and a certain amount of PS-SR is still retained in the lungs after 48 hours. Regardless of the time point, the red fluorescence of the lungs is the strongest, which reflects the advantages of aerosol therapy. Nanomedicines can be effectively delivered to lung tumors through the autonomous breathing of mice, greatly reducing the toxic side effects caused by the retention of nanomedicines in other organs. The mouse lungs were observed under CLSM and their fluorescence was counted, and a consistent conclusion was obtained ( Figure 8 B and C in ).
[0120] In addition, in order to investigate the uptake of PS-SR by lung macrophages, mouse lungs were taken for immunofluorescence staining to observe the co-localization of PS-SR and macrophages. Figure 8 As can be seen from D, whether it is 24 hours or 48 hours, the red fluorescence of cy5.5-labeled PS-SR and the green fluorescence of macrophage labeling are highly overlapped, showing an obvious yellow color, which indicates that the nanomedicine with PS as the carrier successfully achieves targeting to alveolar macrophages, providing a basis for the drugs in it to exert their effects in macrophages.
[0121] 2. Tumor inhibition experiment
[0122] To explore the anti-tumor effect of PS-SR in vivo, the anti-tumor effect of PS-SR was further evaluated in the Balb / c mouse model carrying 4T1. 6 The lung metastasis model was constructed with 4T1 cells, and the mice were divided into model (Blank) group, SHP099 group, R848 group, SHP099+R848 group, and PS-SR group. Six days after modeling, different drugs were given. After the experiment, the lung tissues of the mice were taken for H&E staining, Ki67 and TUNEL staining.
[0123] Blank group: inhaled an equal amount of PBS;
[0124] SHP099 group: 1 mL SHP099 (7.5 mg / kg) was administered by inhalation;
[0125] R848 group: 1 mL R848 (12.5 mg / kg) was administered by inhalation;
[0126] SHP099+R848 group: 1 mL SHP099 (7.5 mg / kg) and R848 (12.5 mg / kg) were administered by inhalation
[0127] PS-SR group: 1 mL PS-SR (28.14 mg / kg) was administered by inhalation. The average weight of mice was 20 g. In the 28.14 mg / kg drug inhaled, the total amount of SHP099 was 150 μg and the total amount of R848 was 250 μg. 224 μl of the original prepared PS-SR nanoparticles were taken and fixed to 1 ml for inhalation.
[0128] Depend on Fig. 9 As can be seen from A, in the group without drug treatment, the Blank group, the mice liver and lungs showed the most tumor cells, while the groups treated with SHP099, R848 or the combination of the two reduced the number of liver and lung tumors to a certain extent, and PS-SR had the strongest tumor inhibition effect on the liver and lungs. At the same time, the white pulp and red pulp of the spleen in the PS-SR group tended to be orderly, reflecting that PS-SR normalizes the body's function by activating the immune system. The mouse lungs were taken for ki67 and tunel staining ( Fig. 9 B), corresponding to the H&E results, PS-SR showed the lowest cell proliferation index and the strongest tumor cell killing ability. This further demonstrates the superior efficacy of PS-SR by transforming macrophages to enhance their anti-tumor ability.
[0129] 3. Immune cell analysis
[0130] To study the in vivo immune effects, mice treated with different drugs were euthanized, and cells from lymph nodes and lung metastases were extracted for immune cell analysis using flow cytometry.
[0131] In lymphoid tissues, cytotoxic T lymphocytes (CD3 + CD8 + ) significantly increased compared with Blank, with the most significant increase in PS-SR ( Fig.10 Figure A). After treatment with PS-SR, helper T lymphocytes (CD3 + CD4 + ) and cytotoxic T cells (CD3 + CD8 + ) significantly increased ( Fig.10 B and Fig.10 C), which indicates that PS-SR treatment activated T cell-related immunotherapy and caused a strong immune response. In addition, due to the expansion of cytotoxic T cells, PS-SR also greatly reduced the percentage of Treg cells ( Fig.10 D).
[0132] Because R848 activates antigen-presenting cells, CD11c in tumor tissues was further detected. + CD80 + CD86 + The number of dendritic cells ( Fig.10 E). As a result, PS-SR greatly increased the maturation of dendritic cells, and the maturation of dendritic cells provided a strong support for the successful activation of T cell immunity.
[0133] In addition, the proportion of macrophages in lung metastases was also detected. Fig.10 As can be seen from the FH in the group treated with SHP099, F4 / 80 + CD206 + The proportion of macrophages decreased, and all R848-containing groups significantly downregulated F4 / 80 + CD206 + The number of macrophages suggests that PS-SR plays a polarizing role in vivo and successfully transforms tumor-promoting macrophages into anti-tumor macrophages.
[0134] 4. Immune cell analysis
[0135] To confirm that PS-SR exerts its anti-tumor effect through its action on macrophages, mice were injected with 1×10 6The lung metastasis model was constructed by using 4T1 cells. The mice were pre-treated with nebulized clodronate liposomes (200 μg), intraperitoneally injected with CD4 neutralizing antibodies (400 μg) and CD8 neutralizing antibodies (400 μg) to deplete antigen-presenting cells and CD4 in the mice. + T cells and CD8 + T cells, and then PS-SR (28.14 mg / kg) was given for treatment. After the treatment, the mouse lungs were taken for H&E staining to observe the number of lung tumors.
[0136] from Fig.11 It can be seen that the Blank group, CD8 neutralizing antibody + PS-SR group and clodronate liposome + PS-SR group had similar therapeutic effects, with almost no tumor inhibition effect. The CD4 neutralizing antibody + PS-SR group had significantly fewer tumor nodules than the Blank group, indicating that the anti-tumor effect of PS-SR mainly depends on the macrophages in the mouse body and the subsequent activation of CD8 + T cell killing, CD4 + T cells play a small role. The PS-SR group without any pre-treatment showed the best anti-tumor efficiency. The experimental results successfully confirmed the design of the present invention: that is, it is effective and reliable to activate the body's immune system to fight tumors by acting on macrophages in the body.
[0137] 5. In vivo biosafety analysis
[0138] The mice were divided into a blank control group, a SHP099 group, a R848 group, and a PS-SR group, and the drugs were administered according to the groups.
[0139] Blank group: inhaled an equal amount of PBS;
[0140] SHP099 group: 1 mL SHP099 (7.5 mg / kg) was administered by inhalation;
[0141] R848 group: 1 mL R848 (12.5 mg / kg) was administered by inhalation;
[0142] PS-SR group: 1 mL PS-SR (28.14 mg / kg) was administered by inhalation.
[0143] After the last administration, the heart, liver, spleen, lung and kidney of the mice were collected for H&E staining to investigate the biosafety of PS-SR in vivo.
[0144] The results of the test are as follows Fig.12 As shown in A, the SHP099, R848 and PS-SR groups did not cause significant damage to the organs and the morphology of each tissue was normal. In addition, the changes in the body weight of the mice were monitored during the treatment period ( Fig.12 B), after drug treatment in each group, the body weight of mice fluctuated slightly, all within the acceptable range (10%-15%). Finally, we extracted blood samples from the mice for biochemical analysis ( Fig.12 C), the biochemical indices of each group remained within the normal range. These results indicate that the systemic toxicity of the therapeutic drug after inhalation therapy is negligible.
[0145] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.
Claims
1. A PS-SR nanoparticle for atomization inhalation, characterized in that: The PS-SR nanoparticles include SHP099, R848 and PS liposomes, and the PS liposomes include brain PS, DSPC and cholesterol; The structural formula of SHP099 is shown in Formula I, and the structural formula of R848 is shown in Formula II; 2. The PS-SR nanoparticles according to claim 1, characterized in that The concentration ratio of SHP099, R848 and PS liposome is 2-4:4-6:3-3.
5.
3. The PS-SR nanoparticles according to claim 1, characterized in that The concentration ratio of brain PS, DSPC and cholesterol in the PS liposome is 4-6:3-5:0.5-2.
4. The PS-SR nanoparticles according to claim 1, characterized in that The preparation method of the PS liposome is: S1, brain PS, DSPC and cholesterol were added to chloroform solution, stirred, and evaporated under reduced pressure to form PS lipid film; S2. The PS lipid membrane is hydrated and purified to form PS liposomes.
5. The method for preparing PS-SR nanoparticles according to any one of claims 1 to 4, characterized in that: The preparation method comprises: S1. Evenly mix an organic solvent containing SHP099 and an organic solvent containing R848 to obtain a mixed solution; S2, adding PS liposomes to the mixed solution, evaporating under reduced pressure to form a PS-SR lipid membrane; S3. The PS-SR lipid film is hydrated and purified to form PS-SR nanoparticles.
6. Use of the PS-SR nanoparticles according to any one of claims 1 to 4 in the preparation of anti-tumor drugs.
7. The use according to claim 6, characterized in that: The dosage form of the drug includes solution, suspension or aerosol.
8. The use according to claim 6, characterized in that: The PS-SR nanoparticles target macrophages and deliver R848 and SHP099 into macrophages to achieve anti-tumor effects.
9. The use according to claim 6, characterized in that: The tumor includes lung cancer metastasis, breast cancer metastasis, colorectal cancer metastasis, gastric cancer metastasis, liver cancer metastasis, pancreatic cancer metastasis or prostate cancer metastasis.
10. A pharmaceutical composition, characterized in that The pharmaceutical composition contains the PS-SR nanoparticles according to any one of claims 1 to 4.
